In the trial patients with metabolic syndrome were treated with Qnexa and experienced a significant average weight loss and a reduction in waist circumference. Significant reductions were also seen in lipid levels.
“Qnexa demonstrated significant weight loss and reduction in waist circumference in this study, coupled with excellent tolerability and a positive impact on certain factors pertaining to metabolic syndrome in obese patients,” commented Leland Wilson, president and CEO of Vivus.
After 24 weeks patients experienced an average weight loss of 26 pounds, as compared to 7 pounds for the placebo group.
Weight loss drugs do not always prodice consistent results and often face product withdrawals. The completion rate for patients on Qnexa over the treatment period was 92%, as compared to 62% for patients in the placebo group.
Metabolic syndrome is a condition characterized by multiple metabolic risk factors, including obesity, blood pressure and cholesterol.